The SS31 Peptide’s Function and Potential Uses

SS-31, also known as elamipretide, is a synthetic four-amino-acid peptide engineered to accumulate inside mitochondria and protect them from the kind of damage that underlies aging, organ failure, and neurodegenerative disease. It works by binding to cardiolipin, a fat molecule on the inner mitochondrial membrane essential for energy production, and stabilizing the membrane structures that keep the cell’s power supply running efficiently. Animal studies across a remarkable range of conditions have shown it can restore energy output, reduce damaging reactive oxygen species, and preserve tissue function. Clinical translation, though, has been slower and more ambiguous than the preclinical results would suggest.

How SS-31 Gets Into Mitochondria and What It Does There

SS-31’s amino acid sequence gives it two properties that explain almost everything it does. It carries positive charges (from its arginine and lysine residues) that are attracted to the negatively charged head groups of cardiolipin on the inner mitochondrial membrane. And it has aromatic residues that physically embed in the lipid layer, anchoring the peptide in place. Molecular simulations show its arginine and lysine side chains sit near the membrane surface among the lipid headgroups, while the aromatic phenylalanine residue buries deeper into the nonpolar core of the membrane.¹ This dual anchoring lets SS-31 bind cardiolipin with high affinity, which researchers confirmed using a fluorescent version of the peptide.²

Why does cardiolipin matter so much? It is the structural backbone of the cristae, the folded inner membranes where the electron transport chain operates. When cardiolipin gets damaged or rearranged, energy production falters and reactive oxygen species leak out, damaging proteins, DNA, and other lipids. By stabilizing cardiolipin, SS-31 keeps the electron transport chain running more efficiently and reduces oxidative stress at its source. One of SS-31’s more interesting features is that it appears to have minimal effect on healthy, normally functioning mitochondria. Its benefits show up almost entirely in cells where something has already gone wrong.³ The compound was discovered somewhat by accident during research into antioxidant peptides, and its selective affinity for cardiolipin on the inner mitochondrial membrane turned out to be the key to its therapeutic potential.⁴

Reversing Age-Related Muscle Decline

Some of the most striking preclinical results with SS-31 have come from aging research in mice. In aged animals, a single injection of SS-31 restored mitochondrial energy production in skeletal muscle to levels indistinguishable from young mice, and it did so within one hour. Resting and maximum ATP production, the coupling efficiency of the energy-producing machinery, and overall cellular energy state all snapped back to youthful levels. Young mice given the same treatment showed no change, consistent with the idea that SS-31 fixes broken mitochondria rather than supercharging healthy ones. After eight days of treatment, aged mice showed meaningfully improved endurance on a treadmill.⁵

Longer treatment periods revealed additional mechanisms. Aged mice given SS-31 showed a broad reversal of oxidative modifications on proteins throughout their skeletal muscle, and their muscles became more fatigue-resistant and gained mass compared to untreated aged controls.⁶ This was not simply because the mitochondria were making more of themselves. Mitochondrial protein levels were unchanged or even slightly reduced after treatment, suggesting that SS-31 was making existing mitochondria work better rather than triggering the cell to build new ones.

Researchers have since identified a more specific mechanism behind these improvements. SS-31 binds directly to the adenine nucleotide translocator, the molecular gate that shuttles ADP into and ATP out of mitochondria. In aged muscle, this transporter becomes less sensitive to ADP, creating a bottleneck in energy production. SS-31 treatment increased ADP uptake through the transporter in old mitochondria and rescued both muscle force production and heart function in aged animals.⁷ The improvement appeared linked to a reduction in oxidative modifications on the transporter protein itself, suggesting that the peptide’s antioxidant effects and its direct binding work hand in hand.

Cardiac Protection Across Multiple Forms of Heart Damage

Heart muscle depends on mitochondria more than almost any other tissue; cardiomyocytes are packed with them. SS-31 has been tested in several animal models of heart disease with consistent positive results. In mice with pressure-overload heart failure (a model mimicking conditions like chronic high blood pressure or aortic stenosis), SS-31 improved cardiac function, reduced the scarring of heart tissue, and boosted levels of a key protein involved in mitochondrial fusion, which helps damaged mitochondria merge and recover.⁸

Ischemia-reperfusion injury, the damage that occurs when blood flow to the heart is restored after a blockage (as during a heart attack or cardiac surgery), is another area of active research. A recent study developed a drug-conjugate that pairs SS-31 with an activator of the cell’s own antioxidant defense system. The conjugate self-assembled into nanofibers in the acidic environment of damaged tissue, releasing SS-31 to protect mitochondria while simultaneously ramping up the cell’s broader antioxidant response. The combination effectively reduced oxidative damage and restored balance in the heart tissue of mice.⁹

SS-31 has also been studied as a protectant against the heart damage caused by doxorubicin, a widely used chemotherapy drug notorious for its cardiotoxicity. In cell and animal models, SS-31 reduced reactive oxygen species levels, stabilized mitochondrial membranes, and decreased the heart cell death and scarring caused by doxorubicin treatment.¹⁰ In rats given doxorubicin long enough to develop dilated cardiomyopathy, early treatment with SS-31 in combination with another heart failure drug preserved cardiac function.¹¹ For cancer patients who need doxorubicin but are at risk of heart damage, this could eventually represent a meaningful advance, though it remains preclinical.

Kidney Disease and Diabetic Nephropathy

The kidneys are metabolically demanding organs, and kidney cells rely heavily on mitochondria to power their filtering work. In diabetic mice, SS-31 reduced protein leakage in urine (a hallmark of kidney damage), shrank the abnormal enlargement of kidney filtering units, and decreased the buildup of scar tissue proteins. It also prevented the kidney cell death triggered by high glucose levels, shifting the balance of pro-death and pro-survival signals back toward survival.¹² A broader review of SS-31 in kidney disease models confirmed that the peptide reduces mitochondrial reactive oxygen species, prevents the collapse of mitochondrial membrane potential, and blocks the opening of permeability transition pores, which are molecular events that lead to cell death when mitochondria fail.³

Neurodegeneration and Brain Inflammation

Mitochondrial dysfunction is a recurring theme in Alzheimer’s disease, and SS-31 has been tested in multiple Alzheimer’s cell and mouse models. In cells carrying a mutation that drives amyloid-beta production (the protein that forms plaques in Alzheimer’s brains), SS-31 treatment lowered levels of both major forms of amyloid-beta, increased mitochondrial DNA copies, and improved cell survival. The effects were even stronger when SS-31 was combined with a mitochondrial fission inhibitor, suggesting the two approaches complement each other.¹³ In a transgenic Alzheimer’s mouse model, long-term SS-31 treatment reversed elevated amyloid-beta levels in the hippocampus, reduced neuronal death and oxidative stress, and preserved synaptic proteins that are critical for memory and communication between brain cells.¹⁴

SS-31 has also shown promise in acute brain inflammation. In a mouse model of sepsis-associated brain dysfunction, the peptide improved cognitive performance and survival rates while reducing hippocampal inflammation and excessive mitochondrial fragmentation in microglia, the brain’s immune cells. The mechanism involved quieting a specific inflammatory pathway that, when overactive, causes collateral damage to brain tissue.¹⁵

Anti-Inflammatory Effects in the Lungs

Mitochondrial damage and inflammation are tightly linked. When mitochondria break down, they release molecules that activate the immune system’s alarm pathways, and one of the most studied of these is the NLRP3 inflammasome. SS-31 has been shown to suppress this pathway in more than one tissue type. In a mouse model of acute lung injury triggered by bacterial toxins, SS-31 reduced inflammation in the lung lining cells and protected against the tissue damage that can escalate into acute respiratory distress syndrome.¹⁶ This anti-inflammatory action is partly a downstream consequence of keeping mitochondria intact. If the mitochondria do not fall apart, they do not release the danger signals that trigger the inflammatory cascade in the first place.

SS-31’s ability to restore mitochondrial quality control extends to mitophagy, the process by which cells identify and recycle damaged mitochondria. In oral epithelial cells exposed to cigarette smoke, SS-31 restored the PINK1/Parkin mitophagy pathway, helping cells clean up their damaged mitochondria rather than letting them accumulate and generate more oxidative stress.¹⁷ This suggests SS-31’s benefits are not limited to directly stabilizing mitochondrial membranes; the peptide also helps the cell’s own repair systems function properly.

Peripheral Vascular Disease and Limb Ischemia

When blood flow to a limb is blocked, the resulting oxygen deprivation damages skeletal muscle mitochondria. In aged mice with hind limb ischemia, SS-31 reduced mitochondrial reactive oxygen species and boosted the expression of antioxidant enzymes in the affected muscle. It also restored a cell-recycling process called autophagy, which helps clear out damaged components and is often disrupted by ischemia.¹⁸ For older patients with peripheral artery disease, who often face both impaired blood flow and age-related mitochondrial decline simultaneously, this dual vulnerability makes the theoretical case for a mitochondrial-targeted treatment especially compelling.

Barth Syndrome and Genetic Mitochondrial Disease

Barth syndrome is a rare genetic condition caused by mutations in the tafazzin gene, which is responsible for remodeling cardiolipin into its mature form. Without functional tafazzin, cardiolipin is malformed, and mitochondria cannot organize their electron transport chain components properly. This makes Barth syndrome a natural test case for a drug that stabilizes cardiolipin interactions. In tafazzin-deficient mice, SS-31 improved mitochondrial respiratory capacity and promoted the organization of electron transport chain supercomplexes without actually changing the abnormal cardiolipin composition itself.¹⁹ In other words, the peptide appeared to compensate for the defective cardiolipin rather than correcting it.

This preclinical work has led to early human use. A case report described an infant diagnosed prenatally with Barth syndrome who developed severe heart failure shortly after birth. Treatment with elamipretide beginning soon after birth was associated with sustained clinical improvement significant enough that the child was moved to inactive status on the heart transplant waiting list.²⁰ A single case cannot prove causation, but the trajectory was dramatic enough to warrant attention for a disease with few treatment options.

Metabolic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (what used to be called non-alcoholic fatty liver disease) is another condition where mitochondrial failure plays a central role. In aged female mice fed a diet designed to induce liver disease, SS-31 treatment improved mitochondrial protein levels and overall liver health. It suppressed inflammatory pathways, improved insulin signaling, and reduced the fat accumulation visible on liver tissue sections.²¹ The same study compared SS-31 head-to-head with MitoQ, another mitochondria-targeted antioxidant that uses a different delivery strategy. MitoQ was stronger at boosting the cell’s own antioxidant defenses, while SS-31 was more effective at preserving mitochondrial structural integrity. Both reduced inflammation and improved insulin sensitivity. The findings suggest these compounds might actually work through complementary rather than redundant mechanisms.

The Clinical Trial Reality

For all the positive preclinical data, the largest human trial of elamipretide delivered mixed results. The MMPOWER-3 trial enrolled patients with primary mitochondrial myopathy, a group of genetic conditions where faulty mitochondria cause progressive muscle weakness. Participants received either elamipretide or placebo for 24 weeks, and the trial measured changes in six-minute walk distance and a patient-reported fatigue score. The trial did not meet either primary endpoint. Across all participants, the difference between drug and placebo in walking distance was negligible.²²

A post hoc analysis, however, told a more nuanced story. Among participants whose mitochondrial disease was caused by mutations in nuclear DNA rather than mitochondrial DNA, those receiving elamipretide walked about 25 meters farther than the placebo group by week 24. This subgroup finding is interesting but carries the usual caveats of post hoc analysis: it was not pre-specified, meaning it could reflect a real biological distinction or a statistical artifact. An earlier dose-escalation trial had established that the drug was generally well-tolerated, with no major safety signals standing out.²³

The gap between animal results and human outcomes is not unusual in drug development, but it is worth understanding why it might be particularly wide here. Mitochondrial diseases are genetically heterogeneous; two patients with the same clinical diagnosis may have entirely different molecular defects. A drug that stabilizes cardiolipin interactions may help some of those defects more than others. The MMPOWER-3 subgroup data hint at exactly this kind of differential response. Future trials may need to be more selective about which patients to enroll, which is a harder and slower path to regulatory approval but may be the honest one.

How SS-31 Differs From Other Mitochondrial Antioxidants

SS-31 is not the only compound designed to get inside mitochondria and reduce oxidative damage, and the differences between approaches matter. MitoQ, probably the best-known alternative, uses a lipophilic molecule (a modified form of coenzyme Q10) attached to a positively charged carrier that drives it into mitochondria based on membrane potential. MitoQ acts primarily as a direct antioxidant, soaking up reactive oxygen species. SS-31, by contrast, works upstream: it stabilizes the membrane structures where electron transport happens, reducing the generation of reactive oxygen species rather than just scavenging them after they form. The head-to-head study in liver disease mice confirmed this distinction. MitoQ was better at upregulating antioxidant enzymes and reducing markers of oxidative damage, while SS-31 was better at preserving the physical architecture of the mitochondria themselves.²¹

This distinction has practical implications. A structural stabilizer like SS-31 might be better suited for conditions where the mitochondrial membrane itself is compromised, such as Barth syndrome or age-related cristae deterioration. A direct antioxidant like MitoQ might work better when the primary problem is excessive oxidative stress with intact membranes. In practice, many diseases involve both problems simultaneously, which is why researchers have speculated about whether combining the two approaches could be synergistic. No combination trials have been published yet, but the rationale is plausible given their distinct mechanisms. For consumers who see MitoQ marketed as a supplement, the comparison is also worth keeping in mind: MitoQ is commercially available as a supplement, while SS-31 remains an investigational drug that is not legally sold outside of clinical trials and compassionate-use programs.